Double-Drug attack shows promise against tough lung cancer
NCT ID NCT03392246
First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors or slow disease in people with advanced EGFR-mutant non-small cell lung cancer who have not yet taken EGFR inhibitors. About 25 participants will receive the combination and be monitored with CT scans. The goal is to see how well the drugs work together and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.